Biovista

18 articles about Biovista

• Quantum-Si and Biovista Partner to Provide AI-Driven Deep Proteomics Insights from the Platinum™ Next-Generation Protein Sequence Platform Output

  1/9/2023

  Quantum-Si and Biovista Partner to Provide AI-Driven Deep Proteomics Insights from the Platinum ™ Next-Generation Protein Sequence Platform Output.

• Biovista Harnesses New Kinds of Augmented and Artificial Intelligence to Address COVID-19

  8/25/2020

  Bioscience firm applies AI and data science to identify existing drugs Atozet and Cablivi as potentially effective therapies for blood clots and inflammation caused by COVID-19

• Artificial Intelligence firm Biovista repositions four promising therapeutics against COVID-19

  4/22/2020

  Biovista, a privately-held AI / bioscience firm best known for drug repositioning, has identified four treatments – two prescription drugs and two over-the-counter compounds — to counter key symptoms of COVID-19.

• Biovista Expands Project Prodigy Collaborations In Personalized Medicine

  8/10/2017

• Biovista Announces Drug Repositioning Collaboration With Astellas

  11/24/2015

• Biovista Sponsors Wylder Nation Foundation's Research On Acid Sphingomyelinase Deficiency

  9/3/2015

• New Biovista Publication: EMR Data Confirm Big Data Analytics Prediction That Hypothyroidism Is A Risk Factor For New-Onset Diabetes Mellitus

  6/23/2015

• Biovista and the CFIDS Association of America Achieve Drug Repositioning Milestone With Pre-IND Meeting

  5/29/2013

• Biovista and Dart Therapeutics Enter into Drug Repositioning Collaboration Targeting Duchenne Muscular Dystrophy

  3/26/2013

• Biovista Awarded Research Grant on Chronic Fatigue Syndrome From the CFIDS Association of America

  3/7/2012

• Pfizer Inc., Biovista Ink Pact to Find New Uses for Established Drugs

  11/10/2010

• Biovista and FDA to Collaborate on a Medication Safety Initiative

  1/12/2010

• Novus Biologicals Awards Contract to Biovista to Drive its Web-Based Novus Explorer Service

  12/17/2009

• Biovista Named Top Innovator in Life Sciences

  12/16/2009

• Biovista Announces Positive Efficacy Results in a Pre-clinical Trial of its BVA-201 Repositioned Drug for Multiple Sclerosis

  9/9/2009

• Biovista Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy

  6/23/2009

• Biovista Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis

  4/2/2009

• Cempra Pharmaceuticals, Inc. and Biovista Enter Agreement for Macrolide Clinical Trial Design Support Studies

  9/30/2008